Cellect Biotechnology (NASDAQ:APOP) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Friday.

Separately, HC Wainwright reissued a “buy” rating and issued a $14.00 price target (up from $12.00) on shares of Cellect Biotechnology in a report on Monday, September 25th.

Shares of Cellect Biotechnology (APOP) traded up $0.32 during trading on Friday, hitting $8.68. 49,849 shares of the stock were exchanged, compared to its average volume of 30,573. Cellect Biotechnology has a 52-week low of $2.30 and a 52-week high of $13.50.

A hedge fund recently bought a new stake in Cellect Biotechnology stock. Susquehanna International Group LLP purchased a new position in Cellect Biotechnology Ltd. (NASDAQ:APOP) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,764 shares of the company’s stock, valued at approximately $101,000. Susquehanna International Group LLP owned approximately 0.23% of Cellect Biotechnology at the end of the most recent quarter. Hedge funds and other institutional investors own 0.69% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/03/cellect-biotechnology-apop-lowered-to-sell-at-valuengine.html.

About Cellect Biotechnology

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cellect Biotechnology Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.